Filing Flows › Health Care › Niagen Bioscience (NAGE)
Niagen Bioscience (NAGE) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Niagen Bioscience (NAGE) Q3 2026 earnings results →
Q3 2026 Revenue down 20% year over year to $27.2M · 4¢ of every $1 of revenue lost · operating margin -5.8%
Niagen Bioscience made $27.2M in Q3 2026 (-20% Y/Y): Consumer Products segment $23.3M, Ingredients segment $3.8M. Operating margin -5.8%, net loss $1.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $27.2M in Q3 2026, down 20% year over year and down 9% from the previous quarter. Consumer Products segment was the largest line at 86% of revenue. Ingredients segment lost $3.4M year over year (down 47%), 50% of the total change.
Gross margin was 62.9%, down 1.6 points from Q3 2025. Operating costs exceeded revenue by $1.6M, an operating margin of -5.8%. Operating expenses grew 6% against a revenue fall of 20%. The fastest-growing cost line was General & admin (+15%). The quarter ended with a net loss of $1.2M, after a profit of $1.0M the previous quarter. Non-operating items added $414K, -35% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.6M (down 29% year over year). Non-cash charges added back $290K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $2.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $27.2M | -20% | -5.8% | −$1.2M | $2.6M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $29.8M | -4% | 2.4% | $963K | $2.8M |
| Q1 2026 | 10-Q | May 6, 2026 | $31.5M | +3% | 5.0% | $6.3M | −$1.2M |
| Q4 2025 | 10-K | Mar 4, 2026 | $33.8M | +16% | 12.1% | $4.1M | $679K |
| Q3 2025 | 10-Q | Nov 4, 2025 | $34.0M | +33% | 12.5% | $4.6M | $3.7M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $31.1M | +37% | 10.2% | $3.6M | $1.2M |
| Q1 2025 | 10-Q | May 7, 2025 | $30.5M | +38% | 15.7% | $5.1M | $7.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Niagen Bioscience
Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries. On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).
In its own words, from its 10-K, filed Mar 4, 2026.
Niagen Bioscience against its Medicinal Chemicals & Botanical Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -20% against the peers' median +7%. Operating margin: -5.8% against the peers' median 0.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NAGE Niagen Bioscience | Q3 2026 | $27.2M | -20% | -5.8% |
| CURLF Curaleaf Holdings | Q3 2026 | $353M | +11% | 0.8% |
| TLRY Tilray Brands | Q1 FY27 | $257M | +23% | -9.4% |
| TRLV Trulieve Cannabis | Q3 2026 | $230M | -20% | 18.5% |
| USNA Usana Health Sciences | Q2 2026 | $223M | -5% | -9.0% |
| AAWH Ascend Wellness Holdings | Q2 2026 | $126M | -0.9% | 4.2% |
| CRON Cronos Group | Q3 2026 | $83.9M | +72% | 10.8% |
| CGC Canopy Growth | Q2 FY27 | $71.1M | +20% | -23.1% |
| JUSH Jushi Holdings | Q3 2026 | $70.5M | +7% | 5.0% |
Source: Niagen Bioscience 10-Q on SEC EDGAR · CIK 1386570 · Medicinal Chemicals & Botanical Products
Guidance and outlook
13F: who owns NAGE and who is buying
More on NAGE
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results